Makes blood purification cartridges for critical illnesses.
Jun 2026Revenue $37.2M/yrExpenses $50.1M/yr
No trendCash runway ≈ 6 months from Jun 2026
Figures by year
When will Cytosorbents be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $37.2M and expenses $50.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $37.1M | $51.8M | −$14.7M |
| Dec 2024 | $35.6M | $52.0M | −$16.5M |
| Dec 2023 | $31.1M | $63.0M | −$31.9M |
| Dec 2022 | $34.7M | $66.2M | −$31.5M |
| Dec 2021 | $43.2M | $65.9M | −$22.7M |
| Dec 2020 | $41.0M | $51.4M | −$10.4M |
| Dec 2019 | $24.9M | $43.9M | −$19.0M |
| Dec 2018 | $22.5M | $38.1M | −$15.6M |
| Dec 2017 | $15.2M | $25.0M | −$9.84M |
| Dec 2016 | $8.21M | $19.7M | −$11.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.